Uploaded July 2026 | Updated November 2026, 4 days ago
Hormone therapy is a real intervention with real indications, and plenty of women who would benefit are not offered it. That is the part the loud voices get right. The overstatement is that estrogen loss makes muscle-building impossible without it, or that one hormone fixes everything. The same 2021 trial shows training builds muscle with or without an estradiol patch. Hormone therapy adds roughly a 5% strength advantage in the meta-analysis, real but modest and still downstream of the training. Testosterone in women has one evidence-based use, low sexual desire; for muscle and bone the benefit shows up only at supraphysiologic, anabolic-steroid-level doses. And the SWAN data put numbers on the “menopause needs its own paradigm” claim: fat gain and lean loss across the transition are real, bounded, and small. There is no special program, because the variables that matter are the same ones that matter for everyone.
0:00 "It's all hormonal and HRT fixes it"
1:16 HRT helps, but training does the work
1:44 Exercise is not a hot-flash cure
2:39 Testosterone in women: what it's for
3:31 "Menopause needs a different paradigm"
4:50 Clinical case: the already-invested patient
Resources:
Menopause Series Part 1 : youtube.com/watch?v=yzk0IkTy0WM
Menopause Series Part 2 — youtube.com/watch?v=YKAlamIOiwU
Menopause Series Part 3 — youtube.com/watch?v=jzoNMQaBAcI
Hypercortisolism episode - open.spotify.com/episode/7tDdUi8dDFWjMYx0fRJdOz
Barbell Medicine coaching and templates: barbellmedicine.com
Signal book pre-order: barbellmedicine.com/shop/learning/signal
Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2009;64(10):1071-1081.
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766.
The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight. 2019;4(5):e124865. doi.org/10.1172/jci.insight.124865
Hormone therapy is a real intervention with real indications, and plenty of women who would benefit are not offered it. That is the part the loud voices get right. The overstatement is that estrogen loss makes muscle-building impossible without it, or that one hormone fixes everything. The same 2021 trial shows training builds muscle with or without an estradiol patch. Hormone therapy adds roughly a 5% strength advantage in the meta-analysis, real but modest and still downstream of the training. Testosterone in women has one evidence-based use, low sexual desire; for muscle and bone the benefit shows up only at supraphysiologic, anabolic-steroid-level doses. And the SWAN data put numbers on the “menopause needs its own paradigm” claim: fat gain and lean loss across the transition are real, bounded, and small. There is no special program, because the variables that matter are the same ones that matter for everyone.
0:00 "It's all hormonal and HRT fixes it"
1:16 HRT helps, but training does the work
1:44 Exercise is not a hot-flash cure
2:39 Testosterone in women: what it's for
3:31 "Menopause needs a different paradigm"
4:50 Clinical case: the already-invested patient
Resources:
Menopause Series Part 1 : youtube.com/watch?v=yzk0IkTy0WM
Menopause Series Part 2 — youtube.com/watch?v=YKAlamIOiwU
Menopause Series Part 3 — youtube.com/watch?v=jzoNMQaBAcI
Hypercortisolism episode - open.spotify.com/episode/7tDdUi8dDFWjMYx0fRJdOz
Barbell Medicine coaching and templates: barbellmedicine.com
Signal book pre-order: barbellmedicine.com/shop/learning/signal
Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2009;64(10):1071-1081.
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766.
The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight. 2019;4(5):e124865. doi.org/10.1172/jci.insight.124865


![The Man Who Couldn’t Stop Gaining Weight | A Medical Mystery
A previously healthy 21-year-old shows up with seven months of headaches and 30-plus pounds of weight gain he can’t explain. He’s eating the same and training more, and the scale climbs anyway. We hand the case to Dr. Austin Baraki cold and work it in real time: the exam, the labs, the MRI, and two diagnoses that turn a headache workup into the clearest proof we’ve got that body weight is set by the brain, not by character. This is the capstone of our weight series (willpower, calories, protein), and it ends on the drug that, this year, did something for these patients that nothing had done before.
Timestamps
• 00:00:00 Cold open: the man who couldn’t stop gaining weight
• 00:01:49 Meet the case (and the rules of the game)
• 00:02:36 The presentation: 21, headaches, unexplained weight gain
• 00:03:57 Austin’s one-liner and how a clinician builds a differential
• 00:05:10 Secondary headaches: what raises the red flag
• 00:13:12 The exam: vitals, and the eye findings that matter
• 00:14:37 The labs, one number at a time
• 00:16:08 Raised pressure and a visual-field clue (bitemporal hemianopia)
• 00:20:45 The MRI
• 00:21:54 First diagnosis: craniopharyngioma
• 00:25:32 The name: a tumor built from tooth tissue
• 00:25:50 Surgery, and what it costs
• 00:27:43 The new mystery: gaining weight faster than ever
• 00:33:41 Second diagnosis: acquired hypothalamic obesity
• 00:39:17 How your brain sets your weight: the POMC brake and the AgRP accelerator
• 00:42:07 What about leptin?
• 00:45:46 Monogenic vs common obesity
• 00:50:30 Why GLP-1 drugs still worked: the brainstem backdoor
• 00:52:11 Responders and non-responders
• 00:55:40 Setmelanotide: a drug for the broken circuit
• 00:56:53 TRANSCEND, and the new FDA approval
• 00:58:55 What it costs
• 01:01:32 Why we care about body fat at all: the garage
• 01:04:36 Flux: which fat is actually dangerous
• 01:09:15 Close
Resources
Barbell Medicine coaching and templates: https://www.barbellmedicine.com
Plus podcast subscription: https://www.barbellmedicine.com/shop/subscriptions/plus-podcast-subscription/
Barbell Medicine Premium: https://www.barbellmedicine.com/shop/subscriptions/barbell-medicine-premium/
Signal (book pre-order): https://www.barbellmedicine.com/shop/learning/signal/
1. Brijmohan A, et al. Acquired hypothalamic obesity following craniopharyngioma resection in a young adult [case report]. 2025. PMCID: PMC12268545; PMID: 40677794.
2. Miller JL, et al; TRANSCEND investigators. Setmelanotide in acquired hypothalamic obesity: a phase 3 randomized trial. N Engl J Med. 2026.
3. Rhythm Pharmaceuticals. FDA approves IMCIVREE (setmelanotide) for acquired hypothalamic obesity. News release. March 19, 2026.
4. US Food and Drug Administration. FDA approves first treatment for weight management for people with certain rare genetic conditions (setmelanotide). 2020.
5. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903-908.
6. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879-884.
7. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155-157.
8. Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085-1095.
9. Clément K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392(6674):398-401.
10. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010;139(2):448-455.
11. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350(25):2549-2557.
12. Guyenet SJ. The Hungry Brain: Outsmarting the Instincts That Make Us Overeat. Flatiron Books; 2017.
Our Sponsors:
* Check out Cometeer and use my code BBM for a great deal: https://www.cometeer.com
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Factor and use my code factormeals.com/bbm50off for a great deal: https://www.factor75.com
* Check out Quince and use my code BBM for a great deal: https://www.quince.com
Advertising Inquiries: https://redcircle.com/brands The Man Who Couldn’t Stop Gaining Weight | A Medical Mystery](https://i.ytimg.com/vi/AmdLuE4IEaU/mqdefault.jpg)
![The Man Who Couldn’t Stop Gaining Weight | A Medical Mystery
A previously healthy 21-year-old shows up with seven months of headaches and 30-plus pounds of weight gain he can’t explain. He’s eating the same and training more, and the scale climbs anyway. We hand the case to Dr. Austin Baraki cold and work it in real time: the exam, the labs, the MRI, and two diagnoses that turn a headache workup into the clearest proof we’ve got that body weight is set by the brain, not by character. This is the capstone of our weight series (willpower, calories, protein), and it ends on the drug that, this year, did something for these patients that nothing had done before.
Timestamps
00:00:00 Cold open: the man who couldn’t stop gaining weight
00:01:49 Meet the case (and the rules of the game)
00:02:36 The presentation: 21, headaches, unexplained weight gain
00:03:57 Austin’s one-liner and how a clinician builds a differential
00:05:10 Secondary headaches: what raises the red flag
00:13:12 The exam: vitals, and the eye findings that matter
00:14:37 The labs, one number at a time
00:16:08 Raised pressure and a visual-field clue (bitemporal hemianopia)
00:20:45 The MRI
00:21:54 First diagnosis: craniopharyngioma
00:25:32 The name: a tumor built from tooth tissue
00:25:50 Surgery, and what it costs
00:27:43 The new mystery: gaining weight faster than ever
00:33:41 Second diagnosis: acquired hypothalamic obesity
00:39:17 How your brain sets your weight: the POMC brake and the AgRP accelerator
00:42:07 What about leptin?
00:45:46 Monogenic vs common obesity
00:50:30 Why GLP-1 drugs still worked: the brainstem backdoor
00:52:11 Responders and non-responders
00:55:40 Setmelanotide: a drug for the broken circuit
00:56:53 TRANSCEND, and the new FDA approval
00:58:55 What it costs
01:01:32 Why we care about body fat at all: the garage
01:04:36 Flux: which fat is actually dangerous
01:09:15 Close
Resources
Barbell Medicine coaching and templates: https://www.barbellmedicine.com
Plus podcast subscription: https://www.barbellmedicine.com/shop/subscriptions/plus-podcast-subscription/
Barbell Medicine Premium: https://www.barbellmedicine.com/shop/subscriptions/barbell-medicine-premium/
Signal (book pre-order): https://www.barbellmedicine.com/shop/learning/signal/
1. Brijmohan A, et al. Acquired hypothalamic obesity following craniopharyngioma resection in a young adult [case report]. 2025. PMCID: PMC12268545; PMID: 40677794.
2. Miller JL, et al; TRANSCEND investigators. Setmelanotide in acquired hypothalamic obesity: a phase 3 randomized trial. N Engl J Med. 2026.
3. Rhythm Pharmaceuticals. FDA approves IMCIVREE (setmelanotide) for acquired hypothalamic obesity. News release. March 19, 2026.
4. US Food and Drug Administration. FDA approves first treatment for weight management for people with certain rare genetic conditions (setmelanotide). 2020.
5. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903-908.
6. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879-884.
7. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155-157.
8. Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085-1095.
9. Clément K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392(6674):398-401.
10. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010;139(2):448-455.
11. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350(25):2549-2557.
12. Guyenet SJ. The Hungry Brain: Outsmarting the Instincts That Make Us Overeat. Flatiron Books; 2017. The Man Who Couldn’t Stop Gaining Weight | A Medical Mystery](https://i.ytimg.com/vi/AsE1MlWU5iA/mqdefault.jpg)






